Back to Search
Start Over
COX-2 inhibitors ameliorate experimental autoimmune encephalomyelitis through modulating IFN-γ and IL-10 production by inhibiting T-bet expression
- Source :
- Journal of Neuroimmunology. 186:94-103
- Publication Year :
- 2007
- Publisher :
- Elsevier BV, 2007.
-
Abstract
- The COX-2 inhibitors Rofecoxib (Rof) and Lumiracoxib (Lum) were evaluated in experimental autoimmune encephalomyelitis (EAE), the model of multiple sclerosis (MS). Administration of Rof and Lum significantly reduced the incidence and severity of EAE, which was associated with the inhibition of MOG 35-55 lymphocyte recall response, anti-MOG 35-55 T cell responses, and modulation of cytokines production. In vitro Rof and Lum inhibited primary T cells proliferation and modulated cytokine production. These findings highlight the fact that Rof and Lum likely prevents EAE by modulating Th1/Th2 response, and suggest its utility in the treatment of MS and other autoimmune diseases.
- Subjects :
- Diclofenac
Encephalomyelitis, Autoimmune, Experimental
Time Factors
T-Lymphocytes
Lymphocyte
medicine.medical_treatment
T cell
Immunology
Lymphocyte Activation
Interferon-gamma
Lactones
Mice
immune system diseases
medicine
Animals
Immunology and Allergy
Sulfones
Rofecoxib
Cell Proliferation
Cyclooxygenase 2 Inhibitors
Dose-Response Relationship, Drug
business.industry
Multiple sclerosis
Experimental autoimmune encephalomyelitis
medicine.disease
In vitro
Interleukin-10
nervous system diseases
Mice, Inbred C57BL
Disease Models, Animal
Interleukin 10
medicine.anatomical_structure
Cytokine
Gene Expression Regulation
Neurology
Female
Neurology (clinical)
T-Box Domain Proteins
business
medicine.drug
Subjects
Details
- ISSN :
- 01655728
- Volume :
- 186
- Database :
- OpenAIRE
- Journal :
- Journal of Neuroimmunology
- Accession number :
- edsair.doi.dedup.....7391478ce6ad4a872bb9d24c60a1977a